All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-CQ1762 | Anti-PIGR (4F3B) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 4F3B | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-CQ5186 | Anti-PIGR (4F3B) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 4F3B | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
CAR-WFY2567 | Anti-PIGR (3F7A9) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 3F7A9 | Mouse | scFv-41BB-CD3ζ | Lentiviral vector | T cell | ||
CAR-WFY5820 | Anti-PIGR (3F7A9) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 3F7A9 | Mouse | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-1022-ZP419 | Anti-PIGR (7F21A1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 7F21A1 | Mouse | scFv-41BB-CD72ζ | Lentiviral vector | T cell | ||
XS-1022-ZP420 | Anti-PIGR (7F21A1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7F21A1 | Mouse | scFv-CD28-CD72ζ | Lentiviral vector | T cell | ||
XS-1022-ZP421 | Anti-PIGR (7F6A1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 7F6A1 | Mouse | scFv-41BB-CD73ζ | Lentiviral vector | T cell | ||
XS-1022-ZP422 | Anti-PIGR (7F6A1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7F6A1 | Mouse | scFv-CD28-CD73ζ | Lentiviral vector | T cell | ||
XS-1022-ZP423 | Anti-PIGR (7F1A1) h(41BB-CD3ζ) CAR, pCDCAR1 | Human | 7F1A1 | Mouse | scFv-41BB-CD74ζ | Lentiviral vector | T cell | ||
XS-1022-ZP424 | Anti-PIGR (7F1A1) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 7F1A1 | Mouse | scFv-CD28-CD74ζ | Lentiviral vector | T cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION